Additional file 2: Figure S2. of Therapeutic potential of TAS-115 via c-MET and PDGFRα signal inhibition for synovial sarcoma

Abstract

SYO-1 and HS-SY-II (PDGFRα-dependent) SS cells were treated with 0.001–10 μM of TAS-115 or control (0.1% DMSO) for 3 h, followed by an additional treatment with 10-ng/ml rhPDGF-BB for the last 15 min. (PPTX 178 kb